CCL2 and type 2 diabetes mellitus: Recently, we showed that plasma levels of MCP-1 and hyperresponsiveness of low-doselipopolysaccharide-induced MCP-1 secretion from monocytes were significantlyreduced by rosiglitazone treatment in patients with type 2 diabetes and seriousvascular disease [15].